Roche Licenses Alzheimer’s Disease Drug Candidate from Evotec in Potential US$830 M Deal
By Heather Cartwright
Pharma Deals Review: Vol 2011 Issue 9 (Table of Contents)
Published: 19 Sep-2011
DOI: 10.3833/pdr.v2011.i9.1544 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Evotec has secured a global licensing agreement with Roche, potentially worth up to US$830 M, for the development and commercialisation of its investigational Alzheimer’s disease drug, EVT-302...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS